Printer Friendly

IMMULOGIC ANNOUNCES PUBLIC OFFERING OF 2 MILLION SHARES OF COMMON STOCK AT $22.75 PER SHARE

IMMULOGIC ANNOUNCES PUBLIC OFFERING OF 2 MILLION SHARES OF COMMON STOCK
 AT $22.75 PER SHARE
 CAMBRIDGE, Mass., Jan. 21 /PRNewswire/ -- ImmuLogic Pharmaceutical Corporation (NASDAQ: IMUL) today announced a public offering of 2 million shares of common stock at a price of $22.75 per share. The net proceeds from the offering will be used for research, development and clinical programs, expansion and relocation of its facilities, and for other general corporate activities.
 Morgan Stanley & Co. Incorporated and Hambrecht & Quist Incorporated are managing the offering. ImmuLogic has granted the underwriters an option to purchase up to 300,000 shares of common stock solely to cover overallotments, if any.
 ImmuLogic is developing products to treat allergies and autoimmune diseases. The company's technical approach is based upon proprietary discoveries and an advanced understanding of the molecular events controlling the human immune system. ImmuLogic is developing a family of ALLERVAX(tm) products to treat allergic diseases and the company has recently announced an agreement with Marion Merrell Dow Inc. to collaborate on the worldwide commercialization of these products. The company is also collaborating with Merck & Co. to develop treatments for Type I diabetes and rheumatoid arthritis.
 A written prospectus may be obtained from the managing underwriters, Morgan Stanley & Co. Incorporated, 1251 Avenue of the Americas, New York, N.Y. 10020, or Hambrecht and Quist Incorporated, One Bush St., San Francisco, Calif. 94104, 415-576-3626.
 -0- 1/21/92
 /CONTACT: Janet C. Bush, vice president-finance and administration, of ImmuLogic Pharmaceutical Corporation, 617-494-0060/
 (IMUL) CO: ImmuLogic Pharmaceutical Corporation ST: Massachusetts IN: MTC SU: OFR


SH -- NE007 -- 1708 01/21/92 10:22 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 21, 1992
Words:267
Previous Article:GOVERNMENT REGULATIONS MAY BE SELF-DEFEATING BY HURTING NEW CAR SALES
Next Article:COMMUNICATIONS SYSTEMS TO ACQUIRE UK APPARATUS COMPANY
Topics:


Related Articles
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
IMMULOGIC FILES REGISTRATION STATEMENT WITH SEC TO SELL 2 MILLION SHARES OF COMMON STOCK
IMMULOGIC PHARMACEUTICAL SELLS 133,000 SHARES THROUGH EXERCISE OF OVER-ALLOTMENT
IMMULOGIC REPORTS FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
IMMULOGIC AND MARION MERRELL DOW SIGN FINAL ALLERVAX PRODUCT COMMERCIALIZATION AGREEMENT
IMMULOGIC REPORTS SECOND QUARTER RESULTS
IMMULOGIC REPORTS SECOND QUARTER RESULTS
GELTEX PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF 2,500,000 SHARES OF COMMON STOCK AT $22.75 PER SHARE
ImmuLogic Reports Fourth Quarter And Year-End 1996 Financial Results
ImmuLogic Reports Second Quarter 1997 Financial Results

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters